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Currently available prognostic tools appear unable to adequately predict recurrence and progression in non muscle-invasive bladder
carcinomas. We aimed to assess the prognostic value of immunohistochemical evaluation of the cell cycle markers p53, p16 and pRb.
Paraffin blocks were obtained from 78 cases of pTa and pT1 transitional cell carcinomas, for which long-term follow-up was available.
Representative sections were stained using antibodies against p53, p16 and pRb. Altered marker expression was found in 45, 17 and
30% of cases, respectively. Concurrent alteration of two or three markers occurred in 19% of cases, and was significantly associated
with grade and stage. In univariate survival analysis, the concurrent alteration of any two markers was significantly associated with
progression. The greatest risk was produced by alteration of both p53 and p16, which increased the risk of progression by 14.45
times (95% confidence interval (CI) 3.10–67.35). After adjusting for grade and stage, this risk was 7.73 (CI 1.13–52.70). The markers
did not generally predict tumour recurrence, except in the 25 pT1 tumours. In these, p16 alteration was associated with a univariate
risk of 2.83 (CI 1.01–7.91), and concurrent p53 and p16 alteration with a risk of 9.29 (CI 1.24–69.50). Overall, we conclude that the
immunohistochemical evaluation of p53 and p16 may have independent prognostic value for disease progression, and may help guide
management decisions in these tumours.
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The clinical course of non muscle-invasive transitional cell
carcinomas of the bladder is unpredictable. Following primary
resection, most patients with pTa or pT1 tumours will develop
recurrences, while around 10–20% will suffer progression to
potentially life-threatening muscle-invasive disease. Conventional
prognostic variables such as grade and stage are unable to
adequately predict which patients will suffer recurrence and
progression, and this leads to difficulty in selecting the most
appropriate management. The identification of a subset of patients
requiring aggressive but curative management, such as cystect-
omy, would be a great advantage. Consequently, much attention
has been focused towards the identification of prognostic markers
of progression and recurrence.
In particular, promise has been shown in the evaluation of
markers associated with the G1/S cell cycle checkpoint. The
proteins p53, p16 and pRb are key components of this checkpoint,
and their examination by immunohistochemistry is a valuable
method for the molecular phenotyping of tumours. In this, altered
expression patterns are used as surrogate indicators of underlying
gene abnormalities. Absence of p16 and pRb expression is a
sensitive means for identifying the statuses of the INK4A and RB
genes, respectively (Zhang et al, 1994; Gorgoulis et al, 1998;
Benedict et al, 1999; Orlow et al, 1999). In addition, recent work
has indicated that elevated expression of pRb may represent
upstream changes leading to pRb phosphorylation and inactiva-
tion, and should also be considered abnormal (Cote et al, 1998;
Grossman et al, 1998). Mutation of the TP53 gene results in the
production of an abnormal p53 protein with a prolonged half-life
(Finlay et al, 1988), which accumulates to concentrations
detectable by immunohistochemistry.
Numerous studies in bladder cancer have established links
between the expression of individual molecular markers and
clinical outcome. However, it has become clear that single markers
provide insufficient predictive power upon which to base manage-
ment decisions for individual patients (Knowles, 2001). Several
recent studies have indicated that evaluation of both p53 and pRb
in bladder cancer provides greater predictive power than can
be obtained from either marker alone (Cordon-Cardo et al, 1997;
Cote et al, 1998; Grossman et al, 1998). Similarly, work by
Korkolopoulou et al (2000) found that together p16 and p53 were
predictive of overall survival in invasive bladder tumours,
whereas individually they were not. In this study we provide, to
our knowledge, the first thorough assessment of p53, p16 and pRb
for their combined prognostic value in a well-characterised cohort
of non muscle-invasive transitional cell carcinomas of the bladder.
MATERIALS AND METHODS
A total of 121 patients were treated for primary non muscle-
invasive transitional cell carcinoma of the bladder at The Royal
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yLondon and St Bartholomew’s Hospitals between 1982 and 1986.
The study population was selected retrospectively from this group
on the basis that (a) original tumour material was available and (b)
satisfactory follow-up data could be obtained. No other exclusion
criteria were made. The resulting cohort comprised 78 patients of
whom 58 (74%) were male. The median age at diagnosis was 66
years (range 24–90), and the median duration of follow-up was 8.0
years (range 3 months–18.2 years). All haematoxylin–eosin
(H&E) sections were examined by a histopathologist (DMB) to
determine grade and stage according to the WHO (Mostofi et al,
1973) and TNM (Sobin and Wittekind, 2002) classifications,
respectively. Representative slides were selected to perform
immunohistochemistry on the corresponding paraffin block.
All patients were treated by transurethral resection with curative
intent. None received intravesical BCG (bacillus Calmette–Guerin)
for primary disease. Follow-up cystoscopies were performed on all
cases initially at 3-monthly intervals, subsequently increased to 6-
monthly intervals according to individual tumour characteristics.
Recurrent disease was treated by transurethral resection/diather-
my, with or without intravesical instillation of BCG.
Definitions for recurrence and progression were set prior to
analysis of the data. Specifically, recurrence was defined as the
reappearance of a biopsy-proven lesion. Progression was defined
as advancement in stage or dedifferentiation to grade 3 disease
(Santos et al, 2003).
Paraffin sections were cut at 3mm. Immunohistochemistry was
performed using a standard avidin–biotin complex (ABC) method
using the Vectastain Universal ABC Elite Kit (Vector Laboratories,
Burlingame, USA). The primary antibodies were p16 (Novocastra
Laboratories Ltd, Newcastle upon Tyne, clone 6H12, dilution 1:50),
pRb (Novocastra Laboratories Ltd, clone 13A10, dilution 1:400),
and p53 (DakoCytomation Ltd, Cambridgeshire, clone DO-7,
dilution 1:100). Sections for p16 and pRb immunohistochemistry
were heated for 4min in 0.01M citrate buffer (pH 6.0). For p53,
antigen retrieval was by overnight incubation in 0.01M citrate buffer
at 601C. Sections were counterstained with Gill’s haematoxylin.
Negative and positive controls were included with each batch. For
negative controls, duplicate sections for each case were stained by
an identical method, except bovine serum albumin with azide was
substituted for the primary antibody solution. Positive controls
included a high-grade invasive breast carcinoma for p53, cervical
intraepithelial neoplasia for p16 and normal tonsil for pRb.
Immunohistochemical evaluation was carried out qualitatively,
by two investigators (DMB and AWH) at a double-headed
microscope, who reached consensus for the percentage of positive
tumour cells in each case. Only nuclear staining was considered
specific for p53 and pRb, and all reactive nuclei were considered
positive irrespective of intensity. For p16, both nuclear and
cytoplasmic staining were included. Evaluation was performed
blind, without knowledge of patient outcome or other clinico-
pathological variables.
Threshold percentages were applied to distinguish between
normal and altered expression patterns, which were established
prior to statistical analysis of the data. Specifically, p53 expression
was defined as altered when at least 20% of cells showed nuclear
staining (Serth et al, 1995; Lacombe et al, 1996; Cordon-Cardo et al,
1997; Sgambato et al, 1999), and p16 was defined as altered if less
than 10% of cells were positive. For pRb, three categories were
defined, as described by Cote et al (1998), namely absent (0%),
normal heterogeneous (1–50%) and elevated (450%). On the
basis that absent and elevated expression were both altered
patterns, these two groups were then combined.
Associations between marker alteration and grade and stage were
examined using Fisher’s exact test and the w
2-test for trend. Survival
curves for progression and recurrence were obtained by the
Kaplan–Meier method, and tested for equivalence by the log-rank
test. Risk ratios and their 95% confidence intervals were calculated
by Cox proportional hazards regression. Results were considered
significant if the two-sided P-value was o0.05. Calculations were
performed using SPSS (release 10.0.5, SPSS Inc, Chicago, USA).
Ethical approval for this study was obtained from East London and
City Health Authority Research Ethics Committee.
RESULTS
For all three antibodies, the pattern of staining was frequently
heterogeneous within a given tumour, with variation in both the
Figure 1 (A) Nuclear staining for p53. (B) Strong immunohistochemical staining for p16. (C) Nuclear staining for pRb.
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ypercentage of positive cells and the intensity of staining (Figure 1).
Usually, the distribution of stained cells appeared random,
although in 19/78 cases (24%) p16 appeared to preferentially stain
the basal cell layers. All negative controls were reviewed for
nonspecific staining, and all positive controls were reviewed to
verify the adequacy of antigen-specific staining.
Cases were classified as normal or altered with respect to their
immunophenotype for each marker. The distribution of cases
between these categories is given in Table 1, which also shows their
relationship with grade and stage. p53 alteration occurred more
frequently in grade 3 and stage pT1 disease (P¼0.026 and 0.007,
respectively, Fisher’s exact test). No statistically significant
associations existed between the markers themselves.
Cases were then further classified according to the number of
markers with altered expression patterns as (a) all expressed
normally, (b) one marker altered, or (c) two or three markers
altered. Normal expression of all three markers was found in 25/78
cases (32%), while 15/78 tumours (19%) showed concurrent
alteration of two or three markers. This index was strongly
associated with both grade and stage (Table 2).
Predictors of progression
Progression to a more aggressive tumour phenotype occurred in
17/78 patients (21.8%) in this series. Grade 3 disease, stage pT1,
and altered p16 expression were significantly associated with
progression (P¼0.003, 0.036, and 0.033, respectively, log-rank
test). Altered p53 expression closely approached significance
(P¼0.064), while pRb alteration was not significant (P¼0.150).
Cox regression was used to calculate univariate relative risks for
each of these variables. The greatest risk was conferred by grade 3
disease, which was associated with a relative risk of 3.88 (95% CI
1.50–10.09) compared to G1/G2 tumours. Stage pT1 increased the
risk of progression by 2.66 times (CI 1.03–6.91) compared to pTa
tumours. The relative risk for progression associated with altered
p53 expression was 2.48 (CI 0.92–6.74), for p16 was 2.98 (CI 1.04–
8.53) and for pRb was 2.01 (CI 0.76–5.28).
Overall, concurrent alteration of any two or three markers was
strongly associated with progression, conferring a relative risk of
6.25 (CI 1.65–23.69, P¼0.007) compared with a normal immu-
nophenotype. To assess the risk associated with specific combina-
tions of marker alterations, relative risks were calculated for each
of the three marker pairings. The greatest risk for progression was
produced by concurrent alteration of p53 and p16 (Table 3). The
five cases with this immunophenotype had a relative risk for
progression of 14.45 (CI 3.10–67.35) compared with tumours in
which both markers were expressed normally. Of the 35 cases with
entirely normal p53/p16 expression, four (11.4%) nevertheless
progressed to a more aggressive phenotype. The progression-free
survival according to p53/p16 status is illustrated in Figure 2. Only
three cases showed concurrent alteration to all three markers, and
accordingly these were not examined as a separate group.
By entering the p53/p16 index with grade and stage in a Cox
regression model, adjusted risk ratios were obtained (Table 4). The
concurrent alteration of both markers produced an adjusted risk
ratio for progression of 7.73 (CI 1.13–52.70). The grade and stage
index did not have independent prognostic value for progression
within this model.
Table 1 Molecular marker status grouped by grade and stage
Grade Stage
Molecular marker
status n G1/2 G3 pTa pT1
p53 P¼0.026 P¼0.007
Normal 43 (55%) 38 (62%) 5 (29%) 35 (66%) 8 (32%)
Altered 35 (45%) 23 (38%) 12 (71%) 18 (34%) 17 (68%)
p16 P¼0.143 P¼0.103
Normal 65 (83%) 53 (87%) 12 (71%) 47 (89%) 18 (72%)
Altered 13 (17%) 8 (13%) 5 (29%) 6 (11%) 7 (28%)
pRb P¼0.130 P¼0.793
Normal 55 (71%) 46 (75%) 9 (53%) 38 (72%) 17 (68%)
Altered 23 (29%) 15 (25%) 8 (47%) 15 (28%) 8 (32%)
P-values obtained by Fisher’s exact test.
Table 2 Combined marker status grouped by grade and stage
Grade Stage
Combined marker
status n G1/2 G3 pTa pT1
Po0.001 P¼0.005
All normal 25 (32%) 22 (36%) 3 (18%) 21 (40%) 4 (16%)
One altered 38 (49%) 34 (56%) 4 (24%) 26 (49%) 12 (48%)
XTwo altered 15 (19%) 5 (8%) 10 (59%) 6 (11%) 9 (36%)
P-values obtained by w
2-test for trend.
Table 3 Relative risks for progression associated with combined marker
status
Variable n Relative risk 95% Confidence interval P
p53/p16
Both normal 35 1.00
One altered 38 2.42 0.76–7.74 0.136
Both altered 5 14.45 3.10–67.35 0.001
p53/pRb
Both normal 32 1.00
One altered 34 1.88 0.56–6.25 0.304
Both altered 12 4.77 1.27–17.84 0.020
p16/pRb
Both normal 46 1.00
One altered 28 2.16 0.78–5.97 0.138
Both altered 4 8.98 1.81–44.44 0.007
Cox proportional hazards regression.
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Figure 2 Kaplan–Meier curve for progression-free survival according to
p53 and p16 status (P-value from log-rank test for trend).
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prognostic value in the presence of the alternative pairings of p53/
pRb and p16/pRb, these variables were added to the above model.
In this case, no variable achieved significance. The p53/p16 index
was closest to the significance level, with concurrent alteration to
the two markers associated with relative risk of 6.44 (CI 0.71–
58.85). By contrast, the risk was 1.76 (CI 0.27–11.66) for
concurrent alteration to p53 and pRb, and 2.44 (CI 0.30–19.94)
for p16 and pRb. G3pT1 tumours were associated with a risk for
progression of 1.67 (CI 0.39–7.08) in this model.
When analysis was restricted to the 53 pTa tumours, none of the
individual markers achieved statistical significance for the
prediction of subsequent tumour progression. The univariate risks
were 2.66 (CI 0.66–10.77) in the case of p53 alteration, 3.37 (CI
0.67–16.82) for p16 alteration, and 1.83 (CI 0.44–7.69) for pRb
alteration. Of note, however, was the prognostic information
provided by the combined p53/p16 index. This was associated with
a relative risk of 2.67 (CI 0.59–12.01) for alteration to either p53 or
p16, and of 15.27 (CI 1.41–165.59) for concurrent alteration to
both markers. On multivariate analysis using a model containing
the p53/p16 index and grade, no variable achieved significance for
independent prognostic value.
The markers were not significant prognostic factors in the 25
pT1 tumours, for which the individual relative risks were 0.95 (CI
0.19–4.76) for p53 alteration, 2.34 (CI 0.55–10.03) for p16, and
1.90 (CI 0.51–7.09) for pRb. The p16/pRb index was the closest to
significance in this cohort, being associated with a relative risk of
1.23 (CI 0.27–5.57) for alteration to either marker, and 5.28 (CI
0.88–31.72) for concurrent alteration to both markers.
Predictors of recurrence
Recurrence occurred in 50/78 patients (64.1%) in this cohort. Cox
regression analysis indicated that neither grade nor stage
significantly predicted recurrence. Grade 3 disease conferred a
relative risk of 1.28 (CI 0.67–2.45) compared to G1/G2 tumours,
while the risk associated with stage pT1 vs pTa was 1.18 (CI 0.66–
2.12). Similarly, analysis of individual molecular markers revealed
no significant differences in recurrence rates between the normal
and altered expression patterns. The relative risk for recurrence
associated with p53 alteration was 0.65 (CI 0.36–1.15), for p16 was
1.54 (CI 0.74–3.19), and for pRb was 1.39 (CI 0.77–2.53).
On examining the molecular markers in pairs, only the
combined p53/p16 status yielded differences in recurrence rates
approaching statistical significance. A single alteration to either
p53 or p16 appeared protective against recurrence, conferring a
relative risk of 0.56 (CI 0.31–1.00) compared with a normal
immunophenotype. Concurrent alteration to both markers, how-
ever, produced a 2.81-fold increase in the risk of recurrence (CI
0.94–8.40). After adjusting for grade and stage, the risk ratios for
recurrence were 0.45 (CI 0.23–0.88) for a single alteration, and
2.21 (CI 0.68–7.19) for alteration to both markers. No other
marker combination was able to improve on the predictive power
of this model.
On confining the analysis to the 53 pTa tumours, no significant
prognostic variables for recurrence were found. However, in the 25
pT1 tumours, p16 alteration was prognostic, increasing the risk of
recurrence by 2.83 times (CI 1.01–7.91). Although p53 alteration
was not individually associated with recurrence, the combination
of p53 and p16 alteration was more informative. This index was
associated with a risk ratio of 0.52 (CI 0.14–1.91) if one marker
was altered, and 9.29 (CI 1.24–69.50) if both markers were altered.
It was not possible to assess this risk satisfactorily against grade in
multivariate analysis due to the absence of G1 tumours within this
cohort. The p53/pRb and p16/pRb indices were not significant
predictors of recurrence in this group.
DISCUSSION
The findings of this study indicate that immunohistochemical
evaluation of p53 and p16 may identify a subset of patients at high
risk for progression to more aggressive disease. This may be of use
in selecting patients for early aggressive therapy. In contrast,
tumour recurrence is not generally predicted by these markers.
p53 expression was altered in 45% of cases, compared with 13–
54% reported for pTa and pT1 bladder cancers in other series
(Cordon-Cardo et al, 1997; Cote et al, 1998; Pfister et al, 1999;
Sgambato et al, 1999; Korkolopoulou et al, 2000). Although high
concordances have been demonstrated between TP53 mutation
and p53 expression (Esrig et al, 1993; Cordon-Cardo et al, 1994;
Gorgoulis et al, 1998), wild-type p53 is also known to be expressed
at detectable levels in some cases. However, given that this state
also correlates with poor prognosis (Abdel-Fattah et al, 1998), its
distinction is probably not important in practice. p53 alteration
was associated with both grade and stage in this series, consistent
with the view that it is a relatively late event in the evolution of the
disease.
Wide variations are seen in the approaches used for evaluation
of p16 staining. Loss of expression has been defined elsewhere as
complete absence of staining in any part of the tumour (Geradts
et al, 1995; Neihans et al, 1999; Santos et al, 2003), overall
immunoreactivity of o5% of nuclei (Friedrich et al, 2001; Yang
et al, 2002), and staining of o50% of nuclei in any part of the
tumour (Korkolopoulou et al, 2000). Many studies disregard
cytoplasmic staining on the assumption that it is nonspecific,
although Benedict et al (1999) have indicated that it is p16-specific.
In our series, the most common pattern was to see both
cytoplasmic and nuclear staining, and in view of the practical
difficulty of dense cytoplasmic staining making assessment of
nuclear staining unreliable, both were counted as positive. Altered
expression was defined as overall positivity of o10% of cells. On
this basis, we identified 13/78 cases as p16-altered (17%), which is
comparable with the 17–25% reported for bladder tumours in
other series (Neihans et al, 1999; Korkolopoulou et al, 2000;
Friedrich et al, 2001).
Recent evidence has indicated that for pRb, both absent (0%)
and elevated (450%) expression should be considered abnormal
(Cote et al, 1998). Using these criteria, we found 30% of cases to be
altered with respect to pRb expression, compared to the higher
figure of 55% reported by Cote et al (1998).
Our findings provide further evidence for the value of
phenotype-associated marker panels over single molecules in
predicting progression in pTa and pT1 bladder cancers. On
univariate analysis, all three markers appeared to be related to
progression, but only p16 alteration was significant in this respect.
p53 alteration closely approached, but did not reach, significance
in this cohort. This result is similar to that of Grossman et al
(1998) but contrasts with others (Serth et al, 1995; Cordon-Cardo
Table 4 Adjusted risks for progression
Variable
Relative
risk
95% Confidence
interval P
p53/p16
Both normal 1.00
One altered 1.77 0.44–7.14 0.420
Both altered 7.73 1.13–52.70 0.037
Grade and stage index
G1/2, pTa 1.00
G3, pTa or G1/2, pT1 1.13 0.25–5.16 0.876
G3, pT1 2.29 0.60–8.74 0.225
Cox proportional hazards regression.
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yet al, 1997), reflecting the sometimes inconsistent relationship seen
between p53 and disease progression in different study cohorts.
However, the concurrent alteration of any two markers was
significantly associated with progression, and conferred a greater
risk than that associated with any marker alone. The pairing of p53
and p16 appeared most useful in this respect, with concurrent
alteration to these two markers conferring almost an eight-fold
increase in the likelihood of disease progression after adjustment
for grade and stage. The index did not provide independent
prognostic information when the alternative pairings of p53/pRb
and p16/pRb were also included in the model, which perhaps
reflects the inherent overlap in the information provided by the
three marker indices.
There remains a need for an improved negative prognostic tool
in these tumours. In this series, however, four of the 35 cases with
normal p53 and p16 expression progressed to a more aggressive
phenotype. Thus, while these markers may have a role in
identifying patients at high risk of progression, it would appear
that they are less suitable for identifying low-risk patients.
In the 53 pTa tumours, the p53/p16 combination remained the
most informative predictive variable on univariate analysis,
although failed to yield significant prognostic information when
assessed against grade in multivariate analysis. The need for
improved prognostic variables is arguably greater in pT1 tumours,
and on analysis of the 25 pT1 tumours in this series the markers
failed to demonstrate significant prognostic value. Nevertheless,
there remained a trend towards a greater risk in tumours with
concurrent alteration to two markers as opposed to those with
single marker alteration, with the p16/pRb index most closely
approaching significance in this respect. We speculate that in a
larger cohort this trend might become significant.
Escape from G1/S checkpoint control is important in malignant
progression, linked with increased proliferative and decreased
apoptotic capacity. Given the complexity of the molecular path-
ways regulating the checkpoint, it seems likely that various degrees
of dysfunction could result from different combinations of
molecular abnormalities. p53, p16 and pRb are key components
in this checkpoint, and as such, their inactivation disrupts its
normal function. By removing collateral and ‘fail-safe’ pathways,
the inactivation of more than one of these molecules might be
expected to increase the severity of this dysfunction. This may
account for the increased predictive power apparently offered by
simultaneous examination of multiple markers in relation to
disease progression.
In contrast, recurrence was not generally associated with the
status of these markers. An interesting exception to this was in the
25 pT1 tumours, in which p16 alteration was prognostic, and
further improved by combined analysis with p53. It would be
unwise to draw conclusions on this from such a small cohort,
however, it is an intriguing point worthy of further exploration.
Other series have found the markers to be largely nonprognostic in
relation to tumour recurrence (Pfister et al, 1999; Korkolopoulou
et al, 2000; Friedrich et al, 2001) and, taken together, these findings
remain broadly consistent with the view that recurrence is dictated
by factors less amenable to prediction by cell cycle markers.
Recurrence may occur by cell seeding from an initial tumour, or
separately from different areas of dysplastic epithelium.
Certain limitations must be borne in mind when drawing
conclusions from these data. Firstly, the evaluation of staining in
this study was qualitative. However, it represents the most likely
method by which such investigations would be interpreted in
routine clinical practice. In this respect, it may have advantages
over formal quantification methods which, although possibly less
subjective, are time-consuming and would probably be impractical
outside a research setting.
Secondly, care must be taken in drawing comparisons with other
studies. In addition to the different approaches for evaluation of
staining mentioned above, differences also exist in the immuno-
histochemistry protocols used between laboratories. This can lead
to variability in results (Fisher et al, 1994; McShane et al, 2000).
The choice of antibody is particularly relevant. Masters et al (2003)
suggest that the DO-7 anti-p53 antibody (Dako), used in the
present study, is less strongly associated with pTa/pT1 bladder
tumour progression than the alternative pAb1801 antibody
(Novocastra). However, they also report the presence of pale but
reproducible staining of some tumours with DO-7, which was not
considered positive for the purpose of analysis, but noted as
meriting further investigation. All intensities of staining were
considered positive in the present study, and we therefore possibly
provide evidence for the value of including such tumours in
survival analyses.
Thirdly, the definition used for bladder tumour progression is
sometimes variable. Most studies define progression as advance-
ment to muscle-invasive disease. However, given that grade 3 and
stage pT1 tumours represent more malignant disease requiring
more aggressive treatment, we set a wider definition to include
progression to such phenotypes. While we believe that this
definition is more applicable to clinical practice than the relatively
narrow definition used elsewhere, the discrepancy must be borne
in mind when comparisons are being drawn.
In spite of these caveats, our findings indicate that patients
with concurrent alteration to both p53 and p16 were at a
significantly higher risk of disease progression than patients
with a normal immunophenotype for these markers, after
adjusting for grade and stage. To our knowledge, this is the first
report of this effect. Moreover, we are not aware of any other study
in which p53, p16 and pRb expression has been characterised in
the same cohort of pTa and pT1 bladder cancers, and assessed
collectively in relation to disease progression. In view of this, it is
noteworthy that the concurrent alteration of p53 and p16 appeared
more informative than alteration of p53 and pRb, for which
prognostic value has already been established (Cordon-Cardo et al,
1997; Cote et al, 1998; Grossman et al, 1998). Given the
significantly increased risk for progression associated with p53
and p16-altered nonmuscle-invasive bladder cancers, patients
presenting with such tumours may be better served by early
treatments such as immunotherapy, chemotherapy or even
cystectomy.
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